

### REMARKS

Applicant has amended the priority claim in the specification. In addition, Applicant has canceled claims 1-60 and added new claims 61-70. The new claims relate to compositions containing an anticoagulant and a protein C or activated protein C polypeptide, wherein the polypeptide contains the amino acid sequence of SEQ ID NO:1 with one, two, three, four, or five substitutions at positions selected from 10, 11, 28, 32, or 33. Support for claims 61-70 can be found throughout Applicant's specification. For example, the sections extending from page 10, line 31 to page 11, line 32, from page 37, line 28 to page 39, line 16, from page 42, line 11 to page 43, line 17, and from page 49, line 8 to page 50, line 5 disclose that a protein C or activated protein C polypeptide can have substitutions at positions that include those recited in the present claims. These sections also teach methods for making and using the polypeptides recited in the present claims. Moreover, the section of Applicant's specification extending from page 18, line 17 to page 19, line 28 disclose that protein C or activated protein C polypeptides can be incorporated into pharmaceutical compositions that also can include anticoagulant agents such as aspirin, warfarin, or heparin. Thus, no new matter has been added.

Applicant asks that claims 61-70 be examined. The enclosed filing fee takes into account the claims pending following entry of this Preliminary Amendment. Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: April 21, 2004

Elizabeth N. Kaytor  
Elizabeth N. Kaytor, Ph.D.  
Reg. No. 53,103

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696